Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [21] Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
    Monk, Bradley J.
    van Mens, Sophie
    Hale, Oliver
    Boer, Jennifer
    van Hees, Frank
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 85 - 98
  • [22] Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer
    Soni, Amy
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2015, 14 (04) : 219 - 226
  • [23] Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis
    Merry, Matthew
    Boulware, David R.
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (12) : 1564 - 1568
  • [24] Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China
    Liao, Xiaodong
    Wu, Yajing
    Lin, Dong
    Gu, Dian
    Luo, Shaohong
    Huang, Xiaoting
    Xu, Xiongwei
    Weng, Xiuhua
    Lin, Shen
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (05) : 881 - 889
  • [25] The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab
    Poellinger, Bernadette
    Haiderali, Amin
    Huang, Min
    Ersoy, Burcu Akyol Akyol
    Abdelaziz, Ahmed H.
    Kassem, Loay
    Elsisi, Gihan Hamdy
    JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 105 - 113
  • [26] Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors
    Steffen Wahler
    Alfred Müller
    Sabine Fuchs
    Johann-Matthias von der Schulenburg
    Health Economics Review, 12
  • [27] Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors
    Wahler, Steffen
    Mueller, Alfred
    Fuchs, Sabine
    von der Schulenburg, Johann-Matthias
    HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [28] Cost-Effectiveness Analysis of Transcatheter Arterial Embolization Techniques for the Treatment of Gastrointestinal Bleeding in the United States
    Razavilar, Negin
    Taleshi, Javad Moradpour
    VALUE IN HEALTH, 2021, 24 (04) : 477 - 485
  • [29] The Cost-effectiveness Analysis of Nurse-Family Partnership in the United States
    Wu, Jinjing
    Dean, Kelsey S.
    Rosen, Zohn
    Muennig, Peter A.
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2017, 28 (04) : 1578 - 1597
  • [30] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
12345